Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.7 years of cash runway.
MAZE Financials Maze Therapeutics, Inc.
2 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$131M | — | — | -$113M | — | $189M |
| 2024 | $168M | $52M | 0.0% | 34.4% | $75M | — | $197M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $20M | -$24M | 0.0% | -132.8% | -$39M | $39M | $199M |
| Dec '25 | — | -$35M | — | — | -$28M | — | $189M |
| Sep '25 | — | -$30M | — | — | -$25M | — | $317M |
| Jun '25 | $0 | -$34M | — | — | -$30M | — | $265M |
| Mar '25 | — | -$33M | — | — | -$30M | — | $294M |
| Dec '24 | $0 | -$30M | — | — | -$23M | — | $197M |
| Sep '24 | $3M | -$25M | 0.0% | -969.2% | -$23M | — | $150M |
| Jun '24 | $165M | $139M | 0.0% | 84.6% | $145M | — | $175M |
| Mar '24 | — | -$32M | — | — | -$24M | — | $30M |
Valuation over time
How the market has priced MAZE against its own fundamentals since 2025-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has risen from 16.9× (Jan '25) to 40.0× (Nov '25).
- The price-to-sales ratio has risen from 5.3× (Jan '25) to 12.5× (Nov '25).
P/E
P/S
Frequently asked questions
Is MAZE growing its revenue and profit?
See the revenue and net-income charts above for Maze Therapeutics, Inc.'s multi-year trend.
How much debt does MAZE have?
As of FY2025, Maze Therapeutics, Inc. reported — of total debt against $189M of cash.
What is MAZE's profit margin?
In FY2025, gross margin was —, operating margin —, and net margin —.
What is MAZE's P/E ratio?
As of Jun '26, Maze Therapeutics, Inc. traded at a price-to-earnings ratio of about 40.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.